Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly.See plans and pricing.See plans →
ProFound Therapeutics secures up to $35 million funding from the Gates Foundation to enhance its platform for tackling preeclampsia and eclampsia.
Aug 28, 2026•about 4 hours ago
Cambridge
Description
ProFound Therapeutics has received an investment commitment of up to $35 million from the Gates Foundation, including an initial investment of $20 million. This funding will support the development of new solutions for women's health through their ProFoundry™ platform. The aim is to discover novel proteins and biomarkers related to preeclampsia and eclampsia. This work is expected to advance the identification of validated biomarkers and therapeutic targets for these conditions.
Company Information
Company
ProFound Therapeutics
Location
Cambridge, Maryland, United States
About
ProFound Therapeutics is pioneering the discovery of a vastly expanded human proteome and using its newfound insights to unlock a universe of potential new medicines. The company’s ProFoundry Platform uses state-of-the-art protein detection technologies to systematically identify and validate proteins and dissect their therapeutic potential. The result is an ever-expanding database of tens of thousands of novel proteins, including their connectivity, functionality, and roles in health and disease. ProFound Therapeutics was founded in 2020 at Flagship Labs, a unit of Flagship Pioneering.
Cambridge